Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

217 public trials 53 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Active, not recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810

Conditions
Classic Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Disease Attributes, +14 more
Locations
  • Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 Mobile, Alabama, United States
  • University of Arkansas for Medical Sciences /ID# 244562 Little Rock, Arkansas, United States
  • Highlands Oncology Group, PA /ID# 245002 Springdale, Arkansas, United States
  • Beverly Hills Cancer Center /ID# 255327 Beverly Hills, California, United States
View all 72 locations
View Trial Details
Active, not recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
View all 57 locations
View Trial Details
Active, not recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, +21 more
Locations
  • University of Arizona Cancer Center - Tucson /ID# 247752 Tucson, Arizona, United States
  • Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232 Miami, Florida, United States
  • Allina Health System /ID# 251782 Minneapolis, Minnesota, United States
  • University of Nebraska Medical Center /ID# 246715 Omaha, Nebraska, United States
View all 20 locations
View Trial Details
Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Double-Expressor Lymphoma, +16 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 634 locations
View Trial Details
Active, not recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Central Alabama Research Birmingham, Alabama, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
  • Florida Cancer Specialists Bonita Springs, Florida, United States
View all 143 locations
View Trial Details
Active, not recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Community Cancer Institute (CCI) Fresno, California, United States
  • Baptist - MD Anderson Cancer Center Jacksonville, Florida, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
View all 63 locations
View Trial Details
Active, not recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • UACC Arizona Tucson, Arizona, United States
  • University of California San Francisco San Francisco, California, United States
  • University of California Los Angeles (UCLA) Santa Monica, California, United States
  • Boca Raton Cancer Research Medical Center Plantation, Florida, United States
View all 175 locations
View Trial Details

Related conditions